Related references
Note: Only part of the references are listed.Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape
Qinghua Wu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)
Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease
Eric Jonasch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
T. K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis
Toni K. Choueiri et al.
NATURE MEDICINE (2021)
Phase II study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, plus cabozantinib for treatment of advanced clear cell renal cell carcinoma (ccRCC)
D. F. McDermott et al.
ANNALS OF ONCOLOGY (2021)
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
T. K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Hereditary Leiomyomatosis and Renal Cell Cancer: Recent Insights Into Mechanisms and Systemic Treatment
Congwang Zhang et al.
FRONTIERS IN ONCOLOGY (2021)
Hypoxia-Inducible Factor-2α as a Novel Target in Renal Cell Carcinoma
Won Seok W. Choi et al.
JOURNAL OF KIDNEY CANCER AND VHL (2021)
HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma
Kevin D. Courtney et al.
CLINICAL CANCER RESEARCH (2020)
Synergies of Antiangiogenic Therapy and Immune Checkpoint Blockade in Renal Cell Carcinoma: From Theoretical Background to Clinical Reality
Xiaohan Zhou et al.
FRONTIERS IN ONCOLOGY (2020)
Targeting the HIF2-VEGF axis in renal cell carcinoma
Toni K. Choueiri et al.
NATURE MEDICINE (2020)
HIF-2α is indispensable for regulatory T cell function
Tzu-Sheng Hsu et al.
NATURE COMMUNICATIONS (2020)
Tumor infiltrating mast cells determine oncogenic HIF-2α-conferred immune evasion in clear cell renal cell carcinoma
Ying Xiong et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma
Rui Xu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications
W. Marston Linehan et al.
NATURE REVIEWS UROLOGY (2019)
Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma
Kevin D. Courtney et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies
Peter Makhov et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pilot study of dovitinib in patients with von Hippel-Lindau disease
Patrick Pilié et al.
Oncotarget (2018)
Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial
Eric Jonasch et al.
LANCET ONCOLOGY (2018)
Prevalence, birth incidence, and penetrance of von Hippel-Lindau disease (vHL) in Denmark
Marie Louise Molgaard Binderup et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2017)
Development of Inhibitors Targeting Hypoxia-Inducible Factor 1 and 2 for Cancer Therapy
Tianchi Yu et al.
YONSEI MEDICAL JOURNAL (2017)
Targeting HIF-2 α in clear cell renal cell carcinoma: A promising therapeutic strategy
Olga Martinez-Saez et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial
S. M. Keefe et al.
ANNALS OF ONCOLOGY (2016)
PT2385, a novel HIF-2a antagonist, combines with checkpoint inhibitor antibodies to inhibit tumor growth in preclinical models by modulating myeloid cells and enhancing T cell infiltration
Guangzhou Han et al.
CANCER RESEARCH (2016)
Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status
Yosra Messai et al.
EUROPEAN UROLOGY (2016)
PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma
Melanie Ruf et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models
Hyejin Cho et al.
NATURE (2016)
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy
A. Ravaud et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: A single-arm, prospective phase II clinical study from the PREDIR group
Stephane Oudard et al.
ONCOTARGET (2016)
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
T. K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
HIF-1α pathway: role, regulation and intervention for cancer therapy
Georgina N. Masoud et al.
ACTA PHARMACEUTICA SINICA B (2015)
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update
Cora N. Sternberg et al.
EUROPEAN JOURNAL OF CANCER (2013)
Development of Inhibitors of the PAS-B Domain of the HIF-2α Transcription Factor
Jamie L. Rogers et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Anthracycline Inhibits Recruitment of Hypoxia-inducible Transcription Factors and Suppresses Tumor Cell Migration and Cardiac Angiogenic Response in the Host
Tetsuhiro Tanaka et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
HIF-1 versus HIF-2 - Is one more important than the other?
Agnieszka Loboda et al.
VASCULAR PHARMACOLOGY (2012)
Genetic and Functional Studies Implicate HIF1α as a 14q Kidney Cancer Suppressor Gene
Chuan Shen et al.
CANCER DISCOVERY (2011)
Phase 3 Trial of Everolimus for Metastatic Renal Cell Carcinoma Final Results and Analysis of Prognostic Factors
Robert J. Motzer et al.
CANCER (2010)
A complex task? Direct modulation of transcription factors with small molecules
Angela N. Koehler
CURRENT OPINION IN CHEMICAL BIOLOGY (2010)
Effects of HIF-1 alpha and HIF2 alpha on Growth andMetabolism of Clear-Cell Renal Cell Carcinoma 786-0 Xenografts
Swethajit Biswas et al.
JOURNAL OF ONCOLOGY (2010)
HIF-α Effects on c-Myc Distinguish Two Subtypes of Sporadic VHL-Deficient Clear Cell Renal Carcinoma
John D. Gordan et al.
CANCER CELL (2008)
Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1 alpha
Mei Y. Koh et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Pseudohypoxic pathways in renal cell carcinoma
Gennady Bratslavsky et al.
CLINICAL CANCER RESEARCH (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Hypoxia-inducible factors in the kidney
Volker H. Haase
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2006)
Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma
RR Raval et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Share Paper
